.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, patients with metastatic intestinal lumps who got biomarker-matched treatments based upon circulating cyst DNA profiling showed a greater professional advantage than those obtaining unequaled treatment.